- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07945860
Conduction System Pacing Versus Conventional Right Ventricular Pacing in Adults With Atrioventricular Block
Randomized Prospective Comparison of Conduction System Pacing Versus Conventional Right Ventricular Pacing in Patients With an Indication for Permanent Pacemaker Implantation
This study compares two ways of pacing the heart in adults with atrioventricular block, a condition in which electrical signals do not pass normally from the upper to the lower heart chambers. Participants must need a permanent pacemaker and have a left ventricular ejection fraction of at least 50% before implantation. Ejection fraction measures how much blood the main pumping chamber ejects with each beat.
The study will include 150 participants at Sheba Medical Center. By chance, 50 participants will receive conduction system pacing, which aims to stimulate the heart through its natural electrical conduction system, and 100 will receive conventional right ventricular pacing. Participants and treating clinicians will know which treatment is used.
The main question is whether the two pacing strategies differ in heart pumping function 24 months after implantation, taking the starting measurement into account. Researchers will also compare quality of life, heart-related emergency visits and hospitalizations, complications, pacemaker and lead function, repeat procedures, and use of healthcare resources.
Heart pumping function will be measured before implantation and at 12 and 24 months. Participants will complete the AQUAREL quality-of-life questionnaire before implantation and at 12, 24, 36, 48, and 60 months. Device follow-up will include routine clinical care and remote monitoring.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Outcomes Over Devices is a prospective, randomized, open-label, two-arm, single-center study comparing conduction system pacing (CSP) with conventional right ventricular pacing (RVP). The clinical indication for permanent pacing is established before recruitment. Randomization is 1:2 (50 CSP; 100 RVP), using a concealed computer-generated sequence with variable block sizes, stratified by baseline left ventricular ejection fraction (LVEF) of 50-59% versus at least 60%, without fixed quotas per stratum.
The primary analysis follows the intention-to-treat principle. The primary estimand is the between-arm difference in LVEF at 24 months, adjusted for baseline LVEF and stratification factors as appropriate. Post-baseline measurements at 12 and 24 months will be analyzed using a repeated-measures model with treatment arm, time, and their interaction. The 12-month evaluation is exploratory. The three AQUAREL domains will be scored and analyzed separately, with baseline adjustment and multiplicity addressed for the secondary 24-month comparisons. Detailed modeling and sensitivity analyses will be prespecified in the statistical analysis plan before unblinded comparative analyses.
Failure to achieve the allocated pacing strategy will not itself exclude a participant. Alternative pacing may be used when clinically necessary, with reasons and actual treatment documented; original allocation remains the basis for intention-to-treat analysis where possible. Actual ventricular pacing burden will be recorded and evaluated in prespecified secondary analyses. An independent Clinical Events Adjudication Committee will review prespecified clinical and device-related events, with arm masking where feasible.
The study is initiated by Sheba Medical Center. Medtronic does not fund the study; CSP systems are purchased under a discounted commercial arrangement. A separate, potentially outcome-based commercial reconciliation after 12 months does not determine clinical treatment or alter randomization, follow-up, data collection, analysis, or publication independence.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Yair Edden, MD
- Telefonnummer: +972-52-6667410
- E-mail: Yair.Edden@sheba.health.gov.il
Studiesteder
-
-
-
Tel HaShomer, Israel
- Sheba Medical Center
-
Ledende efterforsker:
- Yair Edden, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age 18 years or older.
- Clinical indication for permanent pacemaker implantation due to atrioventricular block.
- Pre-implantation echocardiographic left ventricular ejection fraction of at least 50%.
- Ability to understand the study and sign informed consent.
Exclusion Criteria:
- Unable to provide informed consent.
- Estimated life expectancy of less than 12 months.
- Severe medical condition likely to prevent completion of follow-up.
- Existing indication for cardiac resynchronization therapy at recruitment.
- Required pacing system or treatment incompatible with either study arm.
- Concurrent interventional study likely to materially affect study outcomes.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Conduction System Pacing
50 participants allocated to conduction system pacing using a Medtronic SelectSecure MRI SureScan Model 3830 lead placed at the His bundle or left bundle branch area. Final lead position and programming are determined by the implanting electrophysiologist according to anatomy, electrical measurements, and clinical judgment. |
Permanent pacing using a Medtronic SelectSecure MRI SureScan Model 3830 lead targeting His-bundle or left bundle branch area pacing. Final lead placement, fixation, and programming follow electrophysiological measurements and clinical judgment. Where feasible, the same pacemaker generator platform is used in both study arms. |
|
Aktiv komparator: Conventional Right Ventricular Pacing
100 participants allocated to conventional right ventricular pacing using a standard pacing lead and conventional right ventricular lead position, according to usual clinical practice at the study center. Other medical treatment and device programming are determined by clinical need. |
Permanent pacemaker implantation with a conventional right ventricular pacing lead placed at a standard right ventricular site according to usual clinical practice at Sheba Medical Center. Device programming and accompanying medical treatment are determined by clinical need. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Left Ventricular Ejection Fraction at 24 Months
Tidsramme: 24 months after pacemaker implantation.
|
Left ventricular ejection fraction (LVEF), expressed as a percentage and measured by echocardiography at 24 months after implantation. The primary comparison is the between-arm difference adjusted for baseline LVEF and stratification factors as appropriate. The primary analysis follows the intention-to-treat principle. |
24 months after pacemaker implantation.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in AQUAREL Chest Discomfort Domain Score
Tidsramme: Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.
|
Change from baseline in the AQUAREL chest discomfort domain, scored separately using the original algorithm. Domain scores range from 0 to 100; higher scores indicate better quality of life and positive changes indicate improvement. The secondary between-arm comparison at 24 months is adjusted for baseline domain score, with multiplicity addressed across the three domains. The 12-month analysis is exploratory; longer-term scores are also collected. |
Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.
|
|
Change From Baseline in AQUAREL Arrhythmia Domain Score
Tidsramme: Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.
|
Change from baseline in the AQUAREL arrhythmia domain, scored separately using the original algorithm. Domain scores range from 0 to 100; higher scores indicate better quality of life and positive changes indicate improvement. The secondary between-arm comparison at 24 months is adjusted for baseline domain score, with multiplicity addressed across the three domains. The 12-month analysis is exploratory; longer-term scores are also collected. |
Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.
|
|
Change From Baseline in AQUAREL Exertional Dyspnea Domain Score
Tidsramme: Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.
|
Change from baseline in the AQUAREL exertional dyspnea domain, scored separately using the original algorithm. Domain scores range from 0 to 100; higher scores indicate better quality of life and positive changes indicate improvement. The secondary between-arm comparison at 24 months is adjusted for baseline domain score, with multiplicity addressed across the three domains. The 12-month analysis is exploratory; longer-term scores are also collected. |
Before pacemaker implantation (baseline) and at 12, 24, 36, 48, and 60 months after implantation.
|
|
Ventricular Pacing Burden
Tidsramme: Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.
|
Percentage of ventricular beats paced, obtained from device interrogation. Actual pacing burden is an explanatory secondary variable and is not a randomization criterion. |
Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.
|
|
Ventricular Pacing Capture Threshold
Tidsramme: Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.
|
Ventricular capture threshold, expressed in volts, measured during device interrogation. Measurements are recorded with the corresponding device settings to assess pacing performance over follow-up. |
Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.
|
|
Ventricular Sensing Amplitude
Tidsramme: Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.
|
Amplitude of sensed ventricular signals, expressed in millivolts, measured during device interrogation to assess lead and device performance over follow-up. |
Day 1 At pacemaker implantation and at 6, 12, and 24 months after implantation.
|
|
Cardiac or Pacing/Procedure-Related Emergency Department Visits
Tidsramme: From pacemaker implantation through 24 months after implantation (cumulative event count).
|
Number of emergency department visits related to cardiac disease, pacing, or the implantation procedure. Relevant events will be reviewed by the Clinical Events Adjudication Committee under definitions established before enrollment. |
From pacemaker implantation through 24 months after implantation (cumulative event count).
|
|
Cardiac or Pacing/Procedure-Related Hospitalizations
Tidsramme: From pacemaker implantation through 24 months after implantation (cumulative event count).
|
Number of hospital admissions related to cardiac disease, pacing, or the implantation procedure. Relevant events will be reviewed by the Clinical Events Adjudication Committee under definitions established before enrollment. |
From pacemaker implantation through 24 months after implantation (cumulative event count).
|
|
Heart Failure Events
Tidsramme: From pacemaker implantation through 24 months after implantation (cumulative event count).
|
Number of heart failure events during follow-up, reviewed by the Clinical Events Adjudication Committee. Written event definitions and adjudication procedures will be established before enrollment as specified in the protocol. |
From pacemaker implantation through 24 months after implantation (cumulative event count).
|
|
Additional Cardiac Interventions
Tidsramme: From pacemaker implantation through 24 months after implantation (cumulative event count).
|
Number of additional cardiac interventions during follow-up. The indication, date, effects on LVEF or the pacing system, lead changes, and subsequent management will be recorded. Medically necessary interventions are permitted in either study arm. |
From pacemaker implantation through 24 months after implantation (cumulative event count).
|
|
Device-, Lead-, and Procedure-Related Complications
Tidsramme: From pacemaker implantation through 24 months after implantation (cumulative event count).
|
Number of device-, lead-, and procedure-related complications. Events include implantation complications and lead or device problems such as infection, bleeding, pneumothorax, perforation or tamponade, lead dislodgement or fracture, insulation failure, and failure to capture or sense. Major events and relatedness will be reviewed by the Clinical Events Adjudication Committee. |
From pacemaker implantation through 24 months after implantation (cumulative event count).
|
|
Repeat Pacing Procedures, Lead Revisions or Replacements, and System Upgrades
Tidsramme: From pacemaker implantation through 24 months after implantation (cumulative event count).
|
Number of repeat procedures involving the pacing system, including lead revision or replacement and system upgrade. Procedure type, indication, date, and resulting changes to the pacing system will be documented. Events will be reviewed by the Clinical Events Adjudication Committee. |
From pacemaker implantation through 24 months after implantation (cumulative event count).
|
|
Immediate Implantation Success
Tidsramme: During the index implantation procedure
|
Successful implantation of the allocated pacing strategy, reported as the number and percentage of participants meeting the arm-specific technical success criteria. For CSP, assessment includes electrophysiological evidence of conduction-system capture, sensing, capture threshold, and impedance; RVP criteria are specified separately. Numerical thresholds and mandatory tests will be prospectively approved in the electrophysiology operational appendix before first enrollment. |
During the index implantation procedure
|
|
Pacing-System Function
Tidsramme: From implantation through 24 months
|
Device or lead failures identified during clinical follow-up, device interrogation, or remote monitoring, including failure to capture or sense. Failures and subsequent management will be documented and relevant events reviewed by the Clinical Events Adjudication Committee. |
From implantation through 24 months
|
|
Implantation Procedure Duration
Tidsramme: During the index pacemaker implantation procedure.
|
Duration of the index pacemaker implantation procedure, measured in minutes, compared between pacing strategies. |
During the index pacemaker implantation procedure.
|
|
Length of Hospital Stay
Tidsramme: Periprocedural (assessed at discharge from the hospitalization for pacemaker implantation).
|
Duration of the hospital stay associated with the index pacemaker implantation, measured in days. |
Periprocedural (assessed at discharge from the hospitalization for pacemaker implantation).
|
|
Healthcare Resource Use
Tidsramme: Day 1 (pacemaker implantation) through 24 months after implantation.
|
Healthcare resources used for implantation and follow-up, including staff time, equipment, diagnostic tests, and clinical visits. Resource categories will be recorded separately rather than combined into an unvalidated score. Detailed resource definitions and analysis procedures will be finalized in the operational procedures and statistical analysis plan. |
Day 1 (pacemaker implantation) through 24 months after implantation.
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Left Ventricular Ejection Fraction at 12 Months
Tidsramme: 12 months after implantation
|
Left ventricular ejection fraction (LVEF), expressed as a percentage and measured by echocardiography at 12 months after implantation. The 12-month comparison is exploratory; the prespecified primary comparison is at 24 months. |
12 months after implantation
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Yair Edden, MD, Sheba Medical Center
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CTIL-YE-3634-26-SHEBA
- 3634-26-SMC (Anden identifikator: Sheba Medical Center)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .